Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Long-term Safety and Efficacy Study of ACZ885 (Anti-interleukin-1β Monoclonal Antibody) Administered for at Least 6 Months in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

NCT00685373 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00685373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00685373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Long-term Safety and Efficacy Study of ACZ885 (Anti-interleukin-1β Monoclonal Antibody) Administered for at Least 6 Months in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2008
Completion date
April 30, 2010
Enrollment
166 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

cryopyrin-associated periodic syndromes, familial cold autoinflammatory syndrome, muckle wells syndrome, neonatal onset multisystem inflammatory disease